Hassan A Saad*, Mohamed Riad, Ashraf Abdelmonem Elsayed, Rasha S Elsayed, Mohamed E Eraky and Ahmed K El-Taher

Surgical Department, Zagagic University, Sharquia, Egypt

*Corresponding Author: Hassan A Saad, Surgical Department, Zagagic University, Sharquia, Egypt.

Received: July 21, 2023; Published: October 29, 2023

Abstract

Introduction: The most established endocrine problems are thyroid cancer. Differentiated thyroid cancers (DTCs) usually come in papillary and follicular forms [1]. Thyroid cancers are now more time-honored than ever, accounting for 1% of all cancer instances recognized yearly [2]. Follicular kinds have a better impact than aggressive anaplastic types, while follicular types have a higher outlook than papillary types.

Objective: How long-term survival for patients with unique thyroid carcinomas is predicted to be? Age, sex, bulk size, participation of lymph nodes, far away organ metastasis, surgical intervention, and differentiation

Methods: At the medical institution of Zagazig University, the surgical department, 123 patients obtained thyroid surgical process for differentiated carcinoma between 2018 and 2022. (96 for papillary sort most cancers and 27 for follicular kind cancer). Post-operative mortality, histopathology findings (multifocality and differentiation), local and distal lymphatic invasion, Results: Follow-up At the surgical branch of the Zagzig University, ninety-six sufferers with papillary cancer underwent surgery; the typical patient age was once 43.7/-16.0 years, and the male to girl ratio used to be 1:7. The 5-year mortality price after follow-up used to be 90.9% for papillary forms and 84.0% for follicular types, respectively. The average follow-up period was once 4.6/- 4.9 years. Twenty-seven instances (average age: 49.5/- 15.9 years, males: 7, females: 20, male to girl ratio: 0.35%) underwent follicular carcinoma surgery.

Conclusions: Age type of pathological character of thyroid tumor affecting the survival of patients.

 Keywords: Thyroid Malignancy Prevalence; Folly; Color Carcinoma; Papillary Carcinoma; Factors Affecting Survival; Patients Mortality Rate

References

1. Rondeau G and Tuttle RM. “Similarities and differences in follicular cell-derived thyroid cancer management guidelines used in Europe and the United States”. Seminars in Nuclear Medicine2 (2011): 89-95.
2. Haugen BR., et al. “American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer”. Thyroid1 (2016): 1-133.
3. Tuttle RM., et al. “Controversies, Consensus, and Collaboration in the Use of (131)I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association”. Thyroid 4 (2019): 461-470.
4. Brierley JD., et al. “A comparison of different staging systems.' predictability of the patient outcome. Thyroid carcinoma is an example”. Cancer12 (1997): 2414-2423.
5. Tuttle RM., et al. “Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition What Changed and Why?)” Thyroid 6 (2017): 751-756.
6. Nixon IJ., et al. “An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer”. Thyroid 3 (2016): 373-380.
7. Tam S., et al. “Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging Seventh and Eighth Editions”. Thyroid10 (2018): 1301-13010.
8. Randolph GW., et al. “The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension”. Thyroid 11 (2012): 1144-1152.
9. van Velsen EFS., et al. “Comparing the Prognostic Value of the Eighth Edition of the American Joint Committee on Cancer/Tumor Node Metastasis Staging System Between Papillary and Follicular Thyroid Cancer”. Thyroid8 (2018): 976-981.
10. Nava CF., et al. “Impact of the updated TNM staging criteria on prediction of persistent disease in a differentiated thyroid carcinoma cohort”. Archives of Endocrinology and Metabolism1 (2019): 5-11.
11. Tuttle RM., et al. “Estimating the risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system”. Thyroid 12 (2010): 1341-1349.
12. Lamartina L., et al. “Low-risk differentiated thyroid cancer and radioiodine remnant ablation: A systematic review of the literature”. The Journal of Clinical Endocrinology and Metabolism 5 (2015): 1748-1761.
13. Scheffel RS., et al. “The BRAF (V600E) mutation analysis and risk stratification in papillary thyroid carcinoma”. Archives of Endocrinology and Metabolism6 (2021): 751-757.
14. Scheffel RS., et al. “BRAF mutations in thyroid cancer”. Current Opinion in Oncology (2021).
15. Haugen BR., et al. “American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer”. Thyroid1 (2016): 1-133.
16. Sugitani I., et al. “Three different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes”. World Journal of Surgery6 (2010): 1222-1231.
17. Russ G., et al. “European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS”. European Thyroid Journal5 (2017): 225-237.
18. Tuttle RM., et al. “Estimating the risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system”. Thyroid12 (2010): 1341-139.
19. Kwon H., et al. “Active Surveillance for Patients With Papillary Thyroid Microcarcinoma: A Single Center’s Experience in Korea”. The Journal of Clinical Endocrinology and Metabolism6 (2017): 1917-1925.
20. Molinaro E., et al. “Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center”. The Journal of Clinical Endocrinology and Metabolism3 (2020).
21. Rosario PW., et al. “Active Surveillance in Adults with Low-Risk Papillary Thyroid Microcarcinomas: A Prospective Study”. Hormone and Metabolic Research 11 (2011): 703-708.
22. Lamartina L., et al. “Follow-up of low-risk thyroid cancer patients: can we stop follow-up after five years of complete remission?” European Journal of Endocrinology5 (2020): D1-16.
23. Smulever A and Pitoia F. “Active surveillance in papillary thyroid carcinoma: not readily accepted but possible in Latin America”. Archives of Endocrinology and Metabolism5 (2019): 462-469.
24. Tuttle RM., et al. “Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance”. JAMA Otolaryngology – Head and Neck Surgery 10 (2017): 1015-1020.
25. Brito JP., et al. “A Clinical Framework to Facilitate Risk Stratification When Considering an Active Surveillance Alternative to Immediate Biopsy and Surgery in Papillary Microcarcinoma”. Thyroid1 (2016): 144-1449.
26. Ito Y., et al. “Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation”. Thyroid1 (2014): 27-34.
27. Miyauchi A., et al. “Estimating the lifetime probability of disease progression of papillary microcarcinoma of the thyroid during active surveillance”. Surgery 1 (2018): 48-52.
28. Sugitani I., et al. “Indications and Strategy for Active Surveillance of Adult Low-Risk Papillary Thyroid Microcarcinoma: Consensus Statements from the Japan Association of Endocrine Surgery Task Force on Management for Papillary Thyroid Microcarcinoma”. Thyroid 2 (2021): 183-192.
29. Mazeh H., et al. “Familial nonmedullary thyroid carcinoma”. Thyroid 9 (2013): 1049-1056.
30. Ito Y., et al. “Biological behavior and prognosis of familial papillary thyroid carcinoma”. Surgery 1 (2009): 100-105.
31. Lupoli G., et al. “Familial papillary thyroid microcarcinoma: a new clinical entity”. Lancet9153 (1993): 637-639.
32. Uchino S., et al. “Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population”. World Journal of Surgery8 (2002): 897-902.
33. Ballabio M., et al. “Pregnancy-induced changes in thyroid function: role of human chorionic gonadotropin as a putative regulator of maternal thyroid”. The Journal of Clinical Endocrinology and Metabolism4 (1991): 824-831.
34. Shindo H., et al. “Papillary thyroid microcarcinoma might progress during pregnancy”. Thyroid 5 (2014): 840-844.
35. Ito Y., et al. “Effects of Pregnancy on Papillary Microcarcinomas of the Thyroid Reevaluated in the Entire Patient Series at Kuma Hospital”. Thyroid 1 (2016): 156-160.
36. Dias Lopes NM., et al. “Thyroid cancer and autoimmune thyroid disease: A review of molecular aspects and clinical outcomes”. Pathology - Research and Practice 9 (2020): 153098.
37. Vaisman F., et al. “Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer”. Clinical Endocrinology (Oxf)1 (2011): 112-119.
38. Welch HG and Doherty GM. “Saving Thyroids - Overtreatment of Small Papillary Cancers”. The New England Journal of Medicine 4 (2018): 310-312.
39. Adam MA., et al. “The extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients”. Annals of Surgery4 (2014): 601-5; discussion 5-7.
40. Zheng W., et al. “Treatment efficacy between total thyroidectomy and lobectomy for patients with papillary thyroid microcarcinoma: A systemic review and meta-analysis”. European Journal of Surgical Oncology11 (2018): 1679-1684.
41. Thvilum M., et al. “Hypothyroidism is a predictor of disability pension and loss of labor market income: a Danish register-based study”. The Journal of Clinical Endocrinology and Metabolism9 (2014): 3129-3135.
42. Lee SJ., et al. “Risk factors for hypothyroidism and thyroid hormone replacement after hemithyroidectomy in papillary thyroid carcinoma”. Langenbeck's Archives of Surgery 4 (2021): 1223-1231.
43. Hartl DM., et al. “Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer”. Cancers (Basel)11 (2020).
44. Momesso DP., et al. “Dynamic Risk Stratification in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine”. The Journal of Clinical Endocrinology and Metabolism7 (2016): 2692-2700.
45. Liu W., et al. “Continuing controversy regarding individualized surgical decision-making for patients with 1-4 cm low-risk differentiated thyroid carcinoma: A systematic review”. European Journal of Surgical Oncology 12 (2020): 2174-2184.
46. Dueñas JP., et al. “Completion thyroidectomy: is timing important for transcervical and remote access approaches?” World Journal of Otorhinolaryngology – Head and Neck Surgery 3 (2020): 165-170.
47. Youssef MR., et al. “Thyroid lobectomy as a cost-effective approach in low-risk papillary thyroid cancer versus active surveillance”. Surgery (2021).
48. Scheffel RS., et al. “Low Recurrence Rates in a Cohort of Differentiated Thyroid Carcinoma Patients: A Referral Center Experience”. Thyroid8 (2015): 883-889.
49. Schlumberger M., et al. “Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1 5-year follow-up results of a ra missed se 3, equivalence trial”. Lancet Diabetes Endocrinology8 (2021): 618-620.
50. Boucek J., et al. “Occult thyroid carcinoma”. ACTA Otorhinolaryngologica Italica6 (2009): 296-304.
51. Rabal Fueyo A., et al. “Diagnostic Accuracy of ultrasound and fine-needle aspirastudyingstudy of thyroid nodule and multinodular goiter”. Endocrinology, Diabetes and Metabolism 3 (2018): e00024.
52. Wong R., et al. “Thyroid nodules: diagnosis and management”. Medical Journal of Australia 2 (2018): 92-98.
53. Aktas G., et al. “Could red cell distribution width be a marker of thyroid cancer?” Journal of the College of Physicians and Surgeons--Pakistan 9 (2017): 556-558.
54. Sit M., et al. “Neutrophil to lymphocyte ratio is useful in differentiating malign and benign thyroid nodules”. Puerto Rico Health Sciences Journal 1 (2019): 60-63.

Citation

Citation: Hassan A Saad., et al. “Retrospective Study on the Predictive Survival Variables and Therapeutic Response in Differentiated Thyroid Cancer".Acta Scientific Otolaryngology 5.11 (2023): 23-35.

Copyright

Copyright: © 2023 Hassan A Saad., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.